April 6, Shenzhen – Elsevier, a global publisher and leader in information and analytics, has recently announced its list of Highly Cited Chinese Researchers for 2022, which includes four distinguished researchers from BGI Group. 

The Biology Category included three BGI researchers - Wang Jian, Co-founder and Chairman of BGI Group; Yang Huanming, Co-founder, Director and Chairman of BGI Group; and Xu Xun, Executive Director of BGI Group, Director of BGI-Research. Li Bo, CEO of GenoImmune Therapeutics Biotech Ltd., a BGI Group company, was selected for the Clinical Medicine Category. 

In 2022, BGI researchers’ accomplishments led to 112 research papers published in the “CNNS” series (Cell, Nature, The New England Journal of Medicine, Science, and their sister journals). Among them, seven were published in Cell, Nature, and Science. BGI-Research continued to make efforts to digitize life on earth and has contributed to over 39% of the animal and plant genomes sequenced globally by the end of 2022.

The SpatioTemporal Omics Consortium (STOC), of which BGI-Research is a founding partner, has attracted more than 190 leading scientists from 30 countries, with the first batch of research papers published on Cell Press and presented on the STOC webpage as a featured article collection. BGI-Research is a core research arm of BGI Group.

The Highly Cited Chinese Researchers List for 2022 features 5,216 scholars from 504 universities, enterprises, and research institutions.